Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$31.02
-1.8%		$35.92
$13.78
▼
$43.73
$5.48B0.312.02 million shs1.17 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$143.26
+8.1%		$85.11
$41.50
▼
$151.46
$5.92B2.831.42 million shs873,685 shs
Omeros Corporation stock logo
OMER
Omeros
$18.61
+0.8%		$17.12
$4.05
▼
$21.24
$1.34B2.571.43 million shs956,362 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$56.93
+0.1%		$62.41
$22.59
▼
$68.73
$5.36B1.131.57 million shs1.72 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-1.34%+0.51%-8.91%-18.35%+123.57%
GRAIL, Inc. stock logo
GRAL
GRAIL
-5.40%+5.87%+66.14%+91.81%+113.60%
Omeros Corporation stock logo
OMER
Omeros
-2.99%-8.25%-1.49%+99.03%+346.14%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-3.45%-6.22%-13.48%-0.09%+129.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$31.02
-1.8%		$35.92
$13.78
▼
$43.73
$5.48B0.312.02 million shs1.17 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$143.26
+8.1%		$85.11
$41.50
▼
$151.46
$5.92B2.831.42 million shs873,685 shs
Omeros Corporation stock logo
OMER
Omeros
$18.61
+0.8%		$17.12
$4.05
▼
$21.24
$1.34B2.571.43 million shs956,362 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$56.93
+0.1%		$62.41
$22.59
▼
$68.73
$5.36B1.131.57 million shs1.72 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-1.34%+0.51%-8.91%-18.35%+123.57%
GRAIL, Inc. stock logo
GRAL
GRAIL
-5.40%+5.87%+66.14%+91.81%+113.60%
Omeros Corporation stock logo
OMER
Omeros
-2.99%-8.25%-1.49%+99.03%+346.14%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-3.45%-6.22%-13.48%-0.09%+129.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.75
Moderate Buy$51.5666.20% Upside
GRAIL, Inc. stock logo
GRAL
GRAIL
2.33
Hold$102.70-28.31% Downside
Omeros Corporation stock logo
OMER
Omeros
2.71
Moderate Buy$34.0082.70% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.75
Moderate Buy$69.5022.08% Upside

Current Analyst Ratings Breakdown

Latest OMER, GRAL, COGT, and TVTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$105.00 ➝ $175.00
10/1/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$75.00 ➝ $155.00
9/28/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$80.00 ➝ $150.00
9/25/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$65.00 ➝ $100.00
9/24/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/24/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$75.00 ➝ $89.00
9/22/2026
Omeros Corporation stock logo
OMER
Omeros
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Hold (C-)
9/22/2026
Omeros Corporation stock logo
OMER
Omeros
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Overweight$22.00
9/22/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$96.00 ➝ $118.00
9/22/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$76.00
9/22/2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$67.00
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/A$3.84 per shareN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
$147.17M43.48N/AN/A$66.13 per share2.17
Omeros Corporation stock logo
OMER
Omeros
N/AN/A$1.89 per share9.87($1.71) per shareN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$490.73M10.94$0.36 per share156.99$1.28 per share44.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$328.94M-$2.16N/AN/AN/AN/A-84.47%-47.72%11/6/2026 (Estimated)
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$9.75N/AN/AN/A-236.95%-15.88%-14.02%11/11/2026 (Estimated)
Omeros Corporation stock logo
OMER
Omeros
-$3.35M$1.2814.5415.38N/AN/A-164.92%69.41%11/12/2026 (Estimated)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$25.55M-$0.46N/A21.65N/A-7.35%-55.15%-6.88%10/29/2026 (Estimated)

Latest OMER, GRAL, COGT, and TVTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$0.0299N/AN/AN/A$195.68 millionN/A
8/13/2026Q2 2026
Omeros Corporation stock logo
OMER
Omeros
-$0.2683$0.02+$0.2883$0.15$12.69 million$28.53 million
8/10/2026Q2 2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.5550-$0.52+$0.0350-$0.52$0.00 millionN/A
8/5/2026Q2 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.66-$2.56+$0.10-$2.56$42.39 million$44.69 million
8/4/2026Q2 2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.1347-$0.10+$0.0347-$0.37$157.27 million$169.58 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/AN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.48
13.57
13.57
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
10.95
10.95
Omeros Corporation stock logo
OMER
Omeros
N/A
1.95
1.94
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
24.58
4.05
3.99

Institutional Ownership

CompanyInstitutional Ownership
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Omeros Corporation stock logo
OMER
Omeros
48.79%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
6.59%
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Omeros Corporation stock logo
OMER
Omeros
10.50%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.44%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
258173.52 million162.09 millionOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
91044.67 million43.85 millionOptionable
Omeros Corporation stock logo
OMER
Omeros
17572.39 million64.79 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
49794.26 million90.08 millionOptionable

Recent News About These Companies

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
September 30 at 9:58 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-travere-therapeutics-inc-to-contact-law-firm-302893828.html
Critical Survey: Travere Therapeutics (NASDAQ:TVTX) & Vericel (NASDAQ:VCEL)
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31054631
Travere Therapeutics (NASDAQ:TVTX) Earns "Outperform" Rating from Wedbush
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31042940
Travere Therapeutics (TVTX) Sets CEO Handover For December 2026
September 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/travere-therapeutics-tvtx-sets-ceo-011323451.html
Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today
September 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/travere-therapeutics-tvtx-stock-may-141323925.html
Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down - Here's Why
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-travere-therapeutics-nasdaq-tvtx-shares-gap-down-heres-why-2026-09-22/
Travere Therapeutics' (TVTX) "Outperform" Rating Reaffirmed at Wedbush
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-travere-therapeutics-tvtx-outperform-rating-reaffirmed-at-wedbush-2026-09-22/
Travere Therapeutics' (TVTX) Buy Rating Reaffirmed at HC Wainwright
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-travere-therapeutics-tvtx-buy-rating-reaffirmed-at-hc-wainwright-2026-09-22/
Travere Therapeutics, Inc. Announces CEO Changes, Effective December 1, 2026
September 21, 2026  |  marketscreener.comM
Travere Therapeutics Announces Planned Chief Executive Officer Transition
September 21, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260921057187/en/travere-therapeutics-announces-planned-chief-executive-officer-transition/
Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing
September 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/travere-therapeutics-insider-sold-shares-074625088.html
Travere Therapeutics (NASDAQ:TVTX) CAO Sandra Calvin Sells 5,375 Shares
September 18, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-tvtx-insider-buying-and-selling-2026-09-18/
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CAO Sells $335,023.75 in Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-travere-therapeutics-nasdaq-tvtx-cao-sells-33502375-in-stock-2026-09-17/
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) EVP Sells $538,909.74 in Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-travere-therapeutics-nasdaq-tvtx-evp-sells-53890974-in-stock-2026-09-17/
Elizabeth Reed Sells 37,500 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-elizabeth-reed-sells-37500-shares-of-travere-therapeutics-nasdaq-tvtx-stock-2026-09-17/
Jula Inrig Sells 44,674 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-jula-inrig-sells-44674-shares-of-travere-therapeutics-nasdaq-tvtx-stock-2026-09-17/
Travere Therapeutics (NASDAQ:TVTX) CFO Sells $3,148,668.72 in Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-travere-therapeutics-nasdaq-tvtx-cfo-sells-314866872-in-stock-2026-09-17/
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CEO Sells $5,956,165.16 in Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-travere-therapeutics-nasdaq-tvtx-ceo-sells-595616516-in-stock-2026-09-17/
Travere Therapeutics (NASDAQ:TVTX) Insider William Rote Sells 96,198 Shares
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-travere-therapeutics-nasdaq-tvtx-insider-william-rote-sells-96198-shares-2026-09-17/
Peter Heerma Sells 102,190 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-peter-heerma-sells-102190-shares-of-travere-therapeutics-nasdaq-tvtx-stock-2026-09-17/
Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 108,493 Shares
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-travere-therapeutics-nasdaq-tvtx-ceo-eric-dube-sells-108493-shares-2026-09-17/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Broadcom logo displayed on a computer chip embedded in a circuit board with glowing blue connections.
The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
By Leo Miller | September 3, 2026
Illustration of the Braze logo at the center of a diagram connecting customer data icons to email, mobile, and messaging channels.
Braze Beat Expectations—Now 2 SaaS Peers Are in Focus
By Nathan Reiff | September 18, 2026
Gold.com logo with stacked gold bars and an upward-trending candlestick chart in the background.
Gold.com's Q4 Results Show Why This Stock Is More Than a Gold Bet
By Chris Markoch | September 9, 2026
Broadcom logo over a blurred circuit board background.
Broadcom CEO Holds $350B Outlook Strong Amid Calls to Slow Froniter AI Development
By Leo Miller | September 22, 2026
A Marvell-branded semiconductor chip sits on a circuit board illuminated by blue lights.
Can Marvell Keep Up in the Custom AI Chip Race?
By Sam Quirke | September 24, 2026
Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:COGT

$31.02 -0.57 (-1.80%)
Closing price 04:00 PM Eastern
Extended Trading
$30.93 -0.09 (-0.30%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

GRAIL stock logo

GRAIL NASDAQ:GRAL

$143.26 +10.70 (+8.07%)
Closing price 04:00 PM Eastern
Extended Trading
$142.72 -0.54 (-0.38%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Omeros stock logo

Omeros NASDAQ:OMER

$18.61 +0.14 (+0.76%)
Closing price 04:00 PM Eastern
Extended Trading
$18.52 -0.09 (-0.51%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$56.93 +0.08 (+0.14%)
Closing price 04:00 PM Eastern
Extended Trading
$56.92 -0.01 (-0.02%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas